Loading company
Latest annual · FY2020
Millions- Total revenues
- 139
- Operating income
- (55)
- Net income
- (54)
- Free cash flow
- 230
Latest quarter · Q2 FY2021
Millions- Total revenues
- 73
- Operating income
- 16
- Net income
- 17
- Free cash flow
- 11
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2017 to FY2020
- n/m
Translate Bio, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Revenue | $138.8 million | $7.8 million | +1,678.7% | 10-K 2021-03-01 · proof |
| Operating income | -$55.3 million | -$115.8 million | 10-K 2021-03-01 · proof | |
| Net income | -$53.8 million | -$113.3 million | 10-K 2021-03-01 · proof | |
| Cash from operating activities | $236.3 million | -$82.2 million | 10-K 2021-03-01 · proof | |
| Free cash flow | $229.8 million | -$85.7 million | 10-K 2021-03-01 · proof | |
| Total assets | $889.9 million | $336.2 million | +164.7% | 10-K 2021-03-01 · proof |
| Total liabilities | $533.2 million | $182.7 million | +191.9% | 10-K 2021-03-01 · proof |
| Cash and cash equivalents | $342 million | $84.6 million | +304.4% | 10-K 2021-03-01 · proof |
- What was Translate Bio, Inc.'s revenue in fiscal 2020?
- Translate Bio, Inc. reported revenue of $138.8 million for fiscal 2020 (the year ended Dec 31, 2020), against $7.8 million the year before (+1,678.7%). Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
- What was Translate Bio, Inc.'s operating income in fiscal 2020?
- Translate Bio, Inc. reported operating income of -$55.3 million for fiscal 2020 (the year ended Dec 31, 2020), against -$115.8 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
- What was Translate Bio, Inc.'s net income in fiscal 2020?
- Translate Bio, Inc. reported net income of -$53.8 million for fiscal 2020 (the year ended Dec 31, 2020), against -$113.3 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
- What was Translate Bio, Inc.'s cash from operating activities in fiscal 2020?
- Translate Bio, Inc. reported cash from operating activities of $236.3 million for fiscal 2020 (the year ended Dec 31, 2020), against -$82.2 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
- What was Translate Bio, Inc.'s free cash flow in fiscal 2020?
- Translate Bio, Inc. reported free cash flow of $229.8 million for fiscal 2020 (the year ended Dec 31, 2020), against -$85.7 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
- What are Translate Bio, Inc.'s total assets?
- As of Dec 31, 2020, Translate Bio, Inc. reported total assets of $889.9 million, against $336.2 million a year earlier (+164.7%). Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
- What are Translate Bio, Inc.'s total liabilities?
- As of Dec 31, 2020, Translate Bio, Inc. reported total liabilities of $533.2 million, against $182.7 million a year earlier (+191.9%). Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
- What are Translate Bio, Inc.'s cash and cash equivalents?
- As of Dec 31, 2020, Translate Bio, Inc. reported cash and cash equivalents of $342 million, against $84.6 million a year earlier (+304.4%). Source: the 10-K filed with the SEC on Mar 1, 2021. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1693415&period_type=annual&limit=5"Information only, not investment advice.